Myriad Genetics (MYGN) Tops Q4 EPS by 4c

February 28, 2023 5:01 PM EST

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of ($0.12), $0.04 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $177.8 million versus the consensus estimate of $169.47 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities